By Fat Tail Investment Research
By ,
Share
Infant formula producer Bubs Australia [ASX:BUB] reported strong revenue growth in FY22 on underlying EBITDA of $4.8 million.
60% of its $104.2 million FY22 revenue came from BUB’s infant formula segment, which rose 177% year-on-year.
Bubs executive chairman Dennis Lin said the firm expects infant formula revenue will continue to be the ‘major driver behind FY23 growth’, with China and the US its key growth engines.
Despite the results, BUB shares were down nearly 5% in late Tuesday trade.
Year-to-date, BUB shares are up 20%:
www.TradingView.com
Bubs has made the most of the coverage surrounding the US baby formula shortage, where BUB received emergency approval from the FDA to ship its product.
But it wasn’t the US that drove its revenue growth…
In its FY22 accounts, Bubs announced record China gross revenue, which rose 166% year-on-year. China accounted for 55% of group revenue in FY22.
The US revenue contributed 9%.
In a sign of normalising conditions, BUB said corporate daigou revenue rose fivefold in FY21.
The daigou channel was a very important distribution stream for infant formula producers like Bubs and a2 Milk Company [ASX:A2M] wishing to capture China market share.
Here are the key highlights for FY22:
While top-line growth was strong, Bubs was less eager to push its bottom-line performance in its results commentary.
Cash and cash equivalents fell to $16.3 million in FY22 from FY21’s $27.9 million.
Current assets rose by almost $20 million, largely due to a material increase in trade and other receivables, which now stand at $24.9 million, up from $8.7 million.
And while net losses shrunk in FY22, Bubs still ended the year in the red.
The infant formula stock has now accumulated more than $200 million in losses, with FY22 net loss coming in at $11.4 million.
Bub’s CEO Kristy Carr commented on the results:
‘Our domestic market share continued to grow ahead of the category to reach an all-time high. We experienced strong momentum across our China business with a re-engineered and resurgent Corporate Daigou omnichannel model. Additionally, in the last quarter we accelerated our access to the United States with our early acceptance into the Biden-Harris Administrations’ Operation Fly Formula initiative to assist American families during the infant formula shortage crisis.
‘These strong results have been achieved against a backdrop of the lingering impacts of the COVID-19 pandemic, supply chain disruption, inflation and global economic uncertainty. The FY22 result is undoubtedly a reflection of the strong foundations on which our business is built, our agility, and our ability to innovate and leverage opportunities in response to market dynamics.’
Bubs has dubbed itself the ‘fastest growing infant formula manufacturer in Australia’ with market share reaching a new high of 4.7%, according to its accounts.
But as we’ve seen with BNPL, rapid growth is not always a winning strategy.
So can its revenue continue to surge at scale, improving its margins?
Or will the costs of fast growth hinder profitability in the medium term?
Now, let’s move aside from the baby formula market and think about how we drive.
Electric vehicles are likely to be the main way we get around in the future.
And while lithium dominated 2021’s headlines, it also takes the likes of copper, nickel, cobalt, and graphite to make an EV battery hum.
With ASX lithium stocks cooling off this year, our experts believe there may be a smarter way to play the EV boom.
Click here to learn more about what we’re calling lithium’s ‘little brother’.
Regards,
Kiryll Prakapenka
Kiryll Prakapenka is a research analyst focusing on investigating the biggest trends in investments. Kiryll brings sound analytical skills to his work, courtesy of his Philosophy degree from the University of Melbourne. A student of legendary investors and their strategies, Kiryll likes to synthesise macroeconomic narratives with a keen understanding…
Kiryll Prakapenka
Bubs Australia [ASX:BUB] reported record Q4 gross revenue, which rose 278% year-on-year, and 174% quarter-on-quarter, to hit $48.1 million.
Ryan Clarkson-Ledward
Amidst the chaos of the past two years, Aussie investors have seen a handful of trends come and go. But the one trend that has been largely forgotten is baby formula…
Kiryll Prakapenka
Infant formula producer Bubs Australia [ASX:BUB] provided the market with another update regarding its recent emergency supply deal with the US.
Kiryll Prakapenka
[ASX:BUB] is rattling the can to raise $68 million to support ‘growth opportunities.’
Kiryll Prakapenka
Infant nutrition producer Bubs Australia [ASX:BUB] came out with another supplier update today, signing supply agreements with two more US retailers.
Kiryll Prakapenka
On Friday, Bubs Australia [ASX:BUB] has released a ‘materially’ updated guidance for FY22.
Brought to you by
At Money Morning our aim is simple: to give you intelligent and enjoyable commentary on the most important stock market news and financial information of the day — and tell you how to profit from it.
Our goal is simple: to show you stuff about investing and wealth protection that the mainstream is NOT showing you.
Phone: 1300 667 481
Email:
su*****@fa*****.au
Contact Us
About Money Morning
Whitelist Money Morning
FAQ
Terms and Conditions
Financial Services Guide
All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.
Copyright © 2022 Money Morning Australia | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988
About Author
